Exact Sciences reported fourth‑quarter revenue of $878.4 million, up 23% year‑over‑year and ahead of analyst estimates, driven by screening product momentum and growth in precision oncology testing. The company confirmed an upcoming shareholder vote on its $23 billion acquisition by Abbott. CEO Kevin Conroy emphasized continued momentum in core screening products and portfolio expansion. The results reduced near‑term investor concern about growth trajectory ahead of the Abbott merger vote next week.